# Antifibrinolytics


Antifibrinolytics include aprotinin, aminocaproic acid, and **tranexamic acid**. All prevent the breakdown of fibrin (!) by various mechanisms. TXA competitively inhibits plasminogen activator, reducing rate of fibrinolysis.

|Property|Tranexamic Acid (TXA)|
|--|--|
|**Class**| Antifibrinolytic
|**Uses**|Trauma (within 3 hours), cardiac surgery, obstetric surgery, and menorrhagia
|**Presentation**| Tablets, syrup, clear colourless solution for injection
|**Route of Administration**|IV, PO
|**Dosing**| 1g slow IV, which may be followed by infusion of 1g over 8 hours
|**Absorption**|50% bioavailability
|**Distribution**|Low plasma protein binding, V~D~ 9-12 litres
|**Metabolism**| Minimal hepatic metabolism
|**Elimination**|Renal of active drug - dose reduce in renal impairment
|**GIT**|Nausea, vomiting
|**Haematological**|Reduces fibrinolysis, possible increase in DVT/PE
|**Immunological**|Allergic dermatitis

---
## References

1. Peck TE, Hill SA. Pharmacology for Anaesthesia and Intensive Care. 4th Ed. Cambridge University Press. 2014.\
2. [LITFL - Tranexamic Acid](https://lifeinthefastlane.com/ccc/tranexamic-acid/)